Literature DB >> 9399213

Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders.

F Federico1, I L Simone, V Lucivero, G Iliceto, M De Mari, P Giannini, D M Mezzapesa, A Tarantino, P Lamberti.   

Abstract

Proton magnetic resonance spectroscopy (1H-MRS), localized to the lentiform nucleus, was carried out in 12 patients with idiopathic Parkinson's disease (IPD), seven patients with multiple-system atrophy (MSA), seven patients with progressive supranuclear palsy (PSP), and 10 healthy age-matched controls. The study assessed the level of N-acetylaspartate (NAA), creatine-phosphocreatine (Cr), and choline (Cho) in the putamen and globus pallidus of these patients. NAA/Cho and NAA/Cr ratios were significantly reduced in MSA and PSP patients. No significant difference was found between IPD patients and controls. These results suggest an NAA deficit, due to neuronal loss, in the lentiform nucleus of MSA and PSP patients. 1H-MRS is a noninvasive technique that can provide useful information regarding striatal neuronal loss in basal ganglia of patients with atypical parkinsonian disorders and represents a potential tool for diagnosing these disorders.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9399213     DOI: 10.1002/mds.870120611

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  12 in total

Review 1.  Neuroimaging in Parkinson's disease.

Authors:  A Jon Stoessl
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

Review 2.  How to diagnose MSA early: the role of magnetic resonance imaging.

Authors:  K Seppi; M F H Schocke; G K Wenning; W Poewe
Journal:  J Neural Transm (Vienna)       Date:  2005-07-06       Impact factor: 3.575

3.  Utility of susceptibility-weighted MRI in differentiating Parkinson's disease and atypical parkinsonism.

Authors:  Deepak Gupta; Jitender Saini; Chandrasekharan Kesavadas; P Sankara Sarma; Asha Kishore
Journal:  Neuroradiology       Date:  2010-04-01       Impact factor: 2.804

4.  Using 'swallow-tail' sign and putaminal hypointensity as biomarkers to distinguish multiple system atrophy from idiopathic Parkinson's disease: A susceptibility-weighted imaging study.

Authors:  Na Wang; HuaGuang Yang; ChengBo Li; GuoGuang Fan; XiaoGuang Luo
Journal:  Eur Radiol       Date:  2017-01-19       Impact factor: 5.315

Review 5.  Magnetic resonance imaging and magnetic resonance spectroscopy in dementias.

Authors:  Y Y Hsu; A T Du; N Schuff; M W Weiner
Journal:  J Geriatr Psychiatry Neurol       Date:  2001       Impact factor: 2.680

6.  A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease.

Authors:  S D Taylor-Robinson; N Turjanski; S Bhattacharya; J P Seery; J Sargentoni; D J Brooks; D J Bryant; I J Cox
Journal:  Metab Brain Dis       Date:  1999-03       Impact factor: 3.584

Review 7.  Magnetic resonance imaging for the diagnosis of Parkinson's disease.

Authors:  Beatrice Heim; Florian Krismer; Roberto De Marzi; Klaus Seppi
Journal:  J Neural Transm (Vienna)       Date:  2017-04-04       Impact factor: 3.575

8.  Proton Magnetic Resonance Spectroscopy for the Early Diagnosis of Parkinson Disease in the Substantia Nigra and Globus Pallidus: A Meta-Analysis With Trial Sequential Analysis.

Authors:  Wenbin Gu; Chen He; Juping Chen; Junchen Li
Journal:  Front Neurol       Date:  2022-06-16       Impact factor: 4.086

9.  Multiple regional 1H-MR spectroscopy in multiple system atrophy: NAA/Cr reduction in pontine base as a valuable diagnostic marker.

Authors:  H Watanabe; H Fukatsu; M Katsuno; M Sugiura; K Hamada; Y Okada; M Hirayama; T Ishigaki; G Sobue
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-01       Impact factor: 10.154

10.  In vivo evidence of increased nNOS activity in acute MPTP neurotoxicity: a functional pharmacological MRI study.

Authors:  Tiing Yee Siow; Chiao-Chi V Chen; Nina Wan; Kai-Ping N Chow; Chen Chang
Journal:  Biomed Res Int       Date:  2013-08-31       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.